EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Impact of intraoperative dexmedetomidine on clear cell renal cell carcinoma progression: a retrospective cohort study

Ryan Wong, Raj G Patel, Nicolas Cortes-Mejia, Juan J Guerra-Londono, Huang Huang, Satvik Gundre, Nishanth Napa, Juan P Cata

British Journal of Anaesthesia · 2025

DOI: 10.1016/j.bja.2025.02.042 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Anaesthesia, 2025. Verfasst von Ryan Wong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tilman J. Fertitta Family College of Medicine, University of Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Dexmedetomidine, Carcinoma, Renal Cell, Kidney Neoplasms, Intraoperative Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dexmedetomidine, an α-2 adrenoreceptor agonist, is commonly administered during cancer surgery as an adjuvant sedative because of its general anaesthetic agent-sparing effects. We investigated the association between ADRA2 gene expression and dexmedetomidine on oncological outcomes after surgery for clear cell renal cell carcinoma (RCC). METHODS: We conducted an in silico analysis using a publicly available database and a retrospective study in patients with clear cell RCC. The associations between ADRA2A expression and recurrence-free survival and overall survival were analysed. The same outcomes were investigated in a cohort of patients who underwent partial or total nephrectomy and received dexmedetomidine or not. A propensity score matching strategy was utilised to account for selection bias, and a multivariable analysis was performed to control for variables implicated in survival. RESULTS: Expression of the ADRA2A gene at the tumour level was not associated with recurrence-free survival; however, higher levels of expression were significantly associated with shorter overall survival. A total of 1766 patients with clear cell RCC were included in the retrospective study. Dexmedetomidine administration was not associated with higher rates of recurrence or mortality or with a significant impact on recurrence-free survival or overall survival. CONCLUSIONS: Intraoperative administration of dexmedetomidine was not associated with a significant impact on cancer progression and survival. The role of ADRA2A as a prognosis biomarker for clear cell RCC warrants further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineCarcinoma, Renal CellKidney NeoplasmsIntraoperative CareAdrenergic alpha-2 Receptor AgonistsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedReceptors, Adrenergic, alpha-2NephrectomyDisease ProgressionCohort StudiesNeoplasm Recurrence, LocalAdult

Stichwörter der Autor:innen

ADRA2Acancer surgeryclear cell renal cell carcinomadexmedetomidinepostoperative outcomessurvival

Substanzen

DexmedetomidineReceptors, Adrenergic, alpha-2Adrenergic alpha-2 Receptor AgonistsADRA2A protein, human

Autor:innen und Institutionen

  • Tilman J. Fertitta Family College of Medicine, University of Houston, Houston, TX, USA.
  • Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Anesthesiology and Surgical Oncology Research Group, Houston, TX, USA.
  • Anesthesiology and Surgical Oncology Research Group, Houston, TX, USA; Department of Anesthesiology, Henry Ford Health System, Detroit, MI, USA.
  • Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Anesthesiology and Surgical Oncology Research Group, Houston, TX, USA. Electronic address: jc…

Zitieren

APA

Wong, R., Patel, R. G., Cortes-Mejia, N., Guerra-Londono, J. J., Huang, H., Gundre, S., Napa, N., & Cata, J. P. (2025). Impact of intraoperative dexmedetomidine on clear cell renal cell carcinoma progression: a retrospective cohort study. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2025.02.042

Vancouver

Wong R, Patel RG, Cortes-Mejia N, Guerra-Londono JJ, Huang H, Gundre S, et al. Impact of intraoperative dexmedetomidine on clear cell renal cell carcinoma progression: a retrospective cohort study. British Journal of Anaesthesia. 2025. doi:10.1016/j.bja.2025.02.042

BibTeX
@article{Wong2025,
  author = {Wong, Ryan and Patel, Raj G and Cortes-Mejia, Nicolas and Guerra-Londono, Juan J and Huang, Huang and Gundre, Satvik and Napa, Nishanth and Cata, Juan P},
  title = {Impact of intraoperative dexmedetomidine on clear cell renal cell carcinoma progression: a retrospective cohort study},
  journal = {British Journal of Anaesthesia},
  year = {2025},
  doi = {10.1016/j.bja.2025.02.042}
}
Kostenlos starten →